Nrx pharmaceuticals announces new, favorable safety report for zyesami® (aviptadil) in nih sponsored activ-3b critical care study in patients with life-threatening covid-19

Radnor, pa., dec. 14, 2021 (globe newswire) -- nrx pharmaceuticals (nasdaq: nrxp ), a clinical-stage, biopharmaceutical company, today provided a new safety update on zyesami® (aviptadil), which is being tested in the activ-3b critical care phase 3 study sponsored by the us national institutes of health (nih). in its third scheduled analysis, the study's independent data safety monitoring board found no new safety concerns after reviewing a total of 348 patients and recommended continued enrollment.
NRXP Ratings Summary
NRXP Quant Ranking